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Background: Experimental data suggest that mitochondria is involved in tumorigenesis. However, little is known
about the qualitative and quantitative changes of mtDNA in colorectal cancer tissues. We therefore conducted
possible correlations of the mitochondrial DNA (mtDNA) copy number in colorectal cancer (CRC) with clinical and
pathological findings and CRC prognosis.
Methods: mtDNA copy numbers in CRC cancer tissue and adjacent non-cancerous tissue samples were measured
using quantitative real-time polymerase chain reaction analyses from 60 patients admitted to our hospital. We
examined the correlation of mtDNA copy numbers and clinicopathologic parameters of CRC patients. The
correlation between mtDNA copy number and three-year survival was analyzed.
Results: The mtDNA copy number was lower in CRC tissue compared with the corresponding non-cancerous colorectal
tissue (mean: 108.60 ± 20.11 vs. 153.68 ± 25.72) and was significantly correlated with lymph-node metastasis. Patients with
a lower mtDNA copy number tended to have lower 3-year survival than patients with a higher mtDNA copy number
assessed by Kaplan–Meier curves, but the correlation was not significant (overall survival, 63.0 vs 83%).
Conclusions: These results suggest that a reduced copy number of mtDNA is correlated with malignant potential in CRC.
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Mitochondria contain their own genetic systems. Mito-
chondrial DNA (mtDNA) is a 16.569-kb circular double-
stranded molecule used for replication, transcription and
translation [1]. mtDNA is present at thousands of copies
per cell and varies in number according to cell type.
mtDNA programs a small (12S) and large (16S) riboso-
mal RNA gene, 22 transfer RNAs and 13 protein-coding
genes. Mitochondria are responsible for the supply of
most of the energy needed by human cells, and have a
key role in the initiation and execution of apoptosis.
Moreover, mitochondria are the major intracellular pro-
ducers of reactive oxygen species (ROS) and are subject
to direct attack by ROS in the organelles of mammalian
cells. Characteristics such as a lack of introns, inability
to bind to histones, and inefficient mtDNA proofreading* Correspondence: gxm19775555@126.com
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reproduction in any medium, provided the orand DNA repair systems render mtDNA more suscep-
tible to oxidative damage than nuclear DNA (nDNA)
[2]. Impairment of mitochondrial respiratory function
not only reduces the supply of energy (which
may prevent energy-dependent apoptosis) but also
enhances ROS production, which may induce
mutation and oxidative damage to mtDNA. It
has been reported that accumulation of mtDNA
mutations as well as alteration in the execution of
apoptosis contribute to the onset and progression of
various myopathies. Recently, it was reported that
there are common mechanisms by which the bioener-
getic function of mitochondria is altered in cancer
cells. However, little is known about the qualitative
and quantitative changes of mtDNA in the alteration
of mitochondrial oxidative phosphorylation in colorec-
tal cancer tissues.
Colorectal carcinoma (CRC) is the third most preva-
lent cancer and the second highest cause of cancer death
in the world [3]. The life expectancy of individuals with. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CRC is detected. Chemotherapeutic regimens can only
marginally improve the prognosis of advanced cases [4].
To achieve better outcomes for patients, it would be de-
sirable to identify and target cellular molecules involved
in the carcinogenesis of CRC. However, the effect of
CRC on mtDNA copy number is unclear. In the present
study, we investigated the correlation of mtDNA copy
number with the clinicopathologic features and progno-
sis of CRC.
Methods
Informed consent was obtained from each patient
according to the protocols approved by the ethics com-
mittees of 305 Hospital of PLA (Beijing, China). Speci-
mens of CRC (as well as the corresponding normal
margin) from 60 CRC patients diagnosed and treated in
our hospital from January to October 2008 were re-
trieved from the hospital’s pathology department by two
pathologists. All the patients were not receiving pre-
operative radiotherapy and/or chemotherapy, age 22 to
81 years, with an average of 56.7 years old. 30 males and
30 females. I stage six cases, II stage 32 cases, III stage
14 cases, IV stage eight cases (NCCN Classification
Standard); well differentiated 17 cases, differentiated 31
cases, poorly differentiated 12 cases.
DNA extraction
To obtain pure tumor cells from cancerous tissues, laser
capture microdissection (LCM) was used. Each paraffin
block was cut at a thickness of 10 μm into 5 slices.
Genomic DNA was extracted using a QIAamp DNA
Mini Kit (Qiagen, Berlin, Germany).
Real-time quantitative polymerase chain reaction (PCR)
analyses
A precise assay based on fluorogenic real-time quantita-
tive PCR was developed to compare the relative abun-
dance of mtDNA with nuclear DNA. The sequences of
primers used for amplification of ND1 gene in mtDNA
were: forward, 50-TAATGCTTACCGAACGAA-30, re-
verse, 50-TTATGGCGTCAGCGAAGG -30, 104 bp. The
sequences of primers used for amplification of the β-actin
gene in nuclear DNA were: forward, 50-GCAAAGTTC
CCAAGCACA-30, reverse, 50-AAGCAAGCAGCG GA
GCAG-30, 105 bp. The PCR conditions were: hot start at
95°C for 5 min, followed by 40 cycles of 95°C for 30 s,
57°C for 45 s, and 72°C for 45 s. The PCR was carried out
for 40 cycles in a 50 μL reaction mixture containing
200 ng DNA, 200 μM of dNTP, 40 pmol of each primer,
1.0 U of Taq DNA polymerase, 50 mM KCl, 1.5 mM
MgCl2, 10 mM Tris–HCl (pH 9.0), 0.1% Triton X-100,
and 0.1% (w/v) gelatin. The PCR products were separated
by electrophoresis on a 3% agarose gel at 100 V for40 min and detected under UV transillumination after
ethidium bromide staining. The products were cleared
by QIAquick PCR Purification Kit(QIAGEN Germany),
which were combined with pMD 18-T Vector(program
USA), a standard curve was presented by recombinant
plasmids serially diluted 104 to 108 times. The fluores-
cence intensity was measured at the end of each extension
phase at 72°C. The absolute copy number of the target
and internal standard DNAs was analyzed with real-time
quantitative polymerase chain reaction(RT-PCR) using the
SYBR Green method (MJ Research Instrument, USA),
The real-time PCR conditions were: 95°C denaturation for
5 min, 40 cycles of 95°C for 10 s, 60°C for 10 s, 68°C for
20 s. The PCR was carried out for 40 cycles in a 10 μl re-
action mixture containing Sybergreen-I 0.5 μl, 10 × buffer
1 μl, dNTP Mixture 0.25 μl, primer, 2 μl, standard or sam-
ple 1 μl of ddH2O 5.25 μl. The DNA content of the ND1
gene was normalized with that of the β-actin gene in nu-
clear DNA to calculate the copy number of mtDNA in
each sample.
Determination of mtDNA copy number
The nuclear gene β-actin was chosen as the internal ref-
erence for quantifying mtDNA copy number and as a
marker of diploid genome content. ND1 represents the
mtDNA copy number. Standard curves relating mtDNA
and nDNA copies to replication threshold cycles (Ct)
were established using total cellular DNA of CRC tu-
morous cells (Figure 1). For each clinical sample, the Ct
values for mtDNA and nDNA were determined and
their mtDNA and nDNA amounts relative to CRC tu-
morous cells plotted and corrected from the standard
curve. Using the β-actin gene as the internal standard
(whose mtDNA copy number (mtDNA amount/nDNA
amount) was defined as 1), the relative mtDNA copy
numbers of the 60 clinical samples were calculated [5].
The same test was duplicated and mean copy numbers
and standard errors calculated.
Statistical analyses
The chi-square test and non-parametric test were used
to examine the association between mtDNA copy num-
ber and the age and sex of the patient, pathological type
of CRC sample, clinical stage, and metastases to lymph
nodes. Kaplan–Meier and log-rank methods were used
to estimate survival. Statistical significance was set at p
< 0.05.
Results
Generation of standard curves
Standard curves of mtDNA ND1 and the β-actin gene
quantification assay are shown in Figure 1A and B. The
regression line was based on five values ranging from
104 DNA copies to 108 DNA copies, which integrated all
Figure 1 A ND1 quantitative PCR amplification of the power curve in the standard and sample. B β-actin quantitative PCR amplification of
the power curve in the standard and sample.
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relation coefficient (r2) was 0.994 and 0.996 for the
standard curve of mtDNA ND1 and β-actin respectively,
which suggested an acceptable degree of precision for
our quantitative method.
mtDNA copy number of CRC
To evaluate if changes in the quantity of mtDNA oc-
curred within the tumor tissues of CRC patients, we an-
alyzed the mtDNA copy number of tumor tissues and
corresponding non-cancerous colorectal tissues by real-
time quantitative PCR. Forty-two cases of CRCs (70%)
showed reduction of mtDNA copy number compared
with non-cancerous colorectal tissues. The mean mtDNAcopy number in each cell equaled 2ND1/β-actin and was
significantly lower than that in non-cancerous colorectal
tissues. The mean copy number of mtDNA was 108.60 ±
20.11 in tumors and 153.68 ± 25.72 in matched non-
cancerous tissue, respectively.
To further explore the correlation between mtDNA
copy number and the clinicopathological variables of
CRC, we calculated the ratio of the copy number in tu-
mors to that in paired normal tissues. This was desig-
nated as the T/N ratio (mtDNA copy number/β-actin in
T divided by mtDNA copy number/β-actin in N). Based
on the different T/N ratios, patients were categorized
into two subgroups according to the median value of the
T/N ratios (0.72). The association between mtDNA
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ters are summarized in Table 1. Patients with lymph-node
metastasis were more likely to have a lower T/N ratio
compared with patients without lymph-node metastasis,
(p < 0.05). However, there was no significant correlation be-
tween the lower T/N ratio and other characteristics, in-
cluding sex, age, and tumor, node, metastasis (TNM) stage.
Association of mtDNA copy number and patient survival
We then assessed the overall prevalence of survival to
assess the prognostic significance of mtDNA copy num-
ber. The three-year overall survival of 60 patients with
CRC was 78.3%. Kaplan–Meier curves revealed that pa-
tients who had a lower mtDNA copy number (T/N ratio
<0.72) tended to have poorer three-year survival than
patients who had a higher mtDNA copy number (T/N
ratio >0.72) but the difference was not significant. (over-
all survival, 70.0 vs 86.7%; p = 0.082, Figure 2).
Discussion
Mitochondria are cellular organelles bounded by two
distinct membranes. They contain one-tenth of the cel-
lular proteins. Their DNA replicates autonomously and
is transmitted through the maternal germline independ-
ently of nuclear and chromosomal DNA [6]. Each cell in
the human body contains up to several hundred mito-
chondria. Each mitochondrion contains ≤10 copies of
mtDNA. In addition to producing energy, mitochondria
support and participate in several essential cellular func-
tions, including: intermediary metabolism; ion homeo-
stasis; synthesis of lipids, amino acids and nucleotides;
active transport; and apoptosis [7]. The aging process in
humans has been shown to be associated with reduced






Age (years) <57 30
≥57 30
Pathological stage Well differentiated 17
Moderately differentiated 31
Poorly differentiated 12
Lymph node metastasis Positive 17
Negative 43




* It indicated that the low mtDNA copy number correlated significantly with lymphcontent in the brain and lung [8,9]. There are undoubt-
edly tissue-specific effects of aging because the skeletal
muscles and livers of rats showed an age-related decline
in mtDNA copy number. Different from nuclear DNA,
replication of mtDNA is error-prone and mammalian
mtDNA contains no introns, has no protective histones,
and is exposed to deleterious ROS generated by oxida-
tive phosphorylation [10]. These factors contribute to
the accumulation of mutations in mtDNA at an approxi-
mately tenfold greater rate than in nuclear DNA [11].
The mtDNA of tumor cells may not only suffer from the
change of structure but also the change of number.
Some studies have shown that copy number is increased
in tumors. Wang et al. found that the average mtDNA
copy number in pathological low-grade tumours was
over two-fold higher than that in high-grade endometrial
carcinomas, and the Change in mtDNA content was not
related with patients’ age or tumour stages [12]. The
copy number of 1p36.33 and mtDNA peripheral blood
mononuclear cells infected by the Epstein–Barr virus in
patients with lymphocytic leukemia was tested in quanti-
tative PCR by Jeon et al. They suggested that increased
mitochondrial biogenesis is indicative of the progression
of EBV-mediated B-cell transformation [13]. However,
some studies showed that the mtDNA copy number was
decreased in tumors. Lee et al. found: a marked decrease
in cellular mtDNA and ATP content, concomitant with
a lack of mRNAs encoded by mtDNA. The mtDNA- de-
pleted cells showed a decreased sensitivity and accumula-
tion of anti-cancer drugs, suggesting that mtDNA depletion
could develop multidrug resistance (MDR) phenotype in
HCT-8 cells. The expression level of MDR1 mRNA and its
translated product P-glycoprotein was increased in the





Χ2 and Z P
17 12 1.669 0.196
13 18
16 13 0.601 0.438
14 17
5 7 −1.321 0.186
14 17
11 6
12 5 4.022 0.045*
18 25




node metastasis group (P=0.045, Table 1).
Figure 2 Overall survival. Patients who had a lower mtDNA copy number had poorer three-year survival than patients with a higher mtDNA
copy number when assessed by Kaplan–Meier curves, but the difference was not significant (overall survival, 70.0 vs 86.7%, P = 0.082). 0 = low
mtDNA copy number group; 1 = high mtDNA copy number group.
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creasing the stability of MDR1 mRNA expression [14]. Lee
et al. examined three colon cancer cells and found that the
decline in mtDNA copy number may be independent of
tumor-cell homogeneity or heterogeneity of point muta-
tions or large fragment deletion. In human tumors, the in-
stability of the mitochondrial genome and the decline of
mtDNA copy number may be independent factors [15].
Decline in mtDNA copy number may be related to the
reduction in the number of oxidative phosphorylation pro-
teins. In various tumors, reduction of mtDNA copy number
may be correlated with clinicopathological parameters and
tumor invasiveness, For example, compared with normal
liver tissues, the mtDNA copy number in hepatocellular
carcinoma(HCC) was significantly reduced, and the results
showed that it was related to tumor size and cirrhosis. It is
evident that a low mtDNA copy number in HCC patients
might help to identify a poor prognosis [16]. Scientists
could establish cell lines containing varying levels of
mtDNA by treatment with low concentrations of ethidium
bromide. Ethidium bromide can insert into mtDNA mole-
cules and inhibit the activity of mtDNA polymerase gamma
during mtDNA replication. Amuthan and colleagues dem-
onstrated that an invasive phenotype is produced within
the original cell line of the non-invasive mouse skeletal
muscle C1C12 cell line and human lung cancer cell lineA549 if mtDNA is absent, and that the overexpression of
the tumor-specific markers cathepsin L and β-transforming
growth factor can be detected. These studies suggest that
the loss of mtDNA can promote the development and me-
tastasis of tumors [17]. The loss of mtDNA may affect the
development of cancer and cancer metastasis by preventing
apoptosis and promoting the generation of cancer-related
proteins. Wu et al. suggest that somatic mtDNA mutations
and mtDNA depletion occur in gastric cancer and that
mtDNA depletion is involved in carcinogenesis and/or can-
cer progression of gastric carcinoma [18]. Some evidences
suggest that a loss in the integrity of the mitochondrial gen-
ome (sequence and/or copy number) can progress a cancer
to an advanced phenotype by way of ROS dependent and
independent events [19].
Tumor growth requires an appreciable amount of en-
ergy, which is mainly from mitochondrial aerobic oxida-
tion and glycolysis, which is required for excessive cell
proliferation. Previously, it was believed that long-term
hypoxia as well as glycolysis in the tumor played a lead-
ing part in the rapid growth of tumors. Recently, it was
found that these two types of energy supply in tumor
growth have equally important roles. Mitochondria are
the only gene-containing structures outside the nucleus
in eukaryotic cells. The rate of somatic mutation of
mtDNA has been presumed to be 10–100-times greater
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include point mutations, multiple deletions and micro-
satellite instability in coding and non-coding regions.
However, little is known about rapid decreases in
mtDNA, microsatellite instability and alteration of the
copy number in human CRC.
We found that the mean copy number in CRC was
significantly lower than the copy number in adjacent tis-
sues. The copy numbers obtained from the present study
were significantly lower than the copy number of myo-
cardial and peripheral blood mononuclear cells reported
from other studies [5,20]. We also found that the de-
crease in mtDNA copy number was significantly corre-
lated with lymph-node metastasis but not with sex, age,
pathological type, or TNM stage. We also found that the
three-year tumor-free survival was lower among CRC
patients with lower mtDNA copy numbers. This may be
because the low copy numbers in tumors result in a stron-
ger tolerance to hypoxia. Therefore, tumors can reduce the
dependence of mitochondrial oxidative phosphorylation.
Hence, the main source of energy for tumor progression is
rendered to anaerobic metabolism in the glycolytic path-
way. This is a favorable measure for tumor invasion, and
which is a necessary condition for survival of the tumor
under hypoxic conditions [21]. Tumors with relatively high
copy numbers of mtDNA have poor tolerance to hypoxia
grow slowly, they are less invasive, and more sensitive to
chemotherapy. Thus, patients with such tumors have a bet-
ter prognosis [22], Tumors that metastasize to lymph
nodes are more likely to recur even after surgical removal.
We found that the copy number of mtDNA was negatively
correlated with lymph-node metastasis. Patients with a
relatively high copy number of mtDNA had a higher three-
year tumor-free survival than patients with a lower copy
number of mtDNA. but the difference was not significant.
The small sample size might limit the significance of our
study. A future should focus on a functional analysis of the
reduction of mtDNA in CRC.Conclusions
In conclusion, these results suggest that a reduced
copy number of mtDNA is correlated with malignant
potential in Colorectal Cancer and the copy number of
mtDNA was negatively correlated with lymph-node
metastasis.
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